Molecular imaging kits for hexosamine biosynthetic pathway in oncology

Current Medicinal Chemistry

Volumn 19, Issue 20, 2012, Pages 3310-3314

  Yang, David J ^a   Kong, Fan Lin ^a   Oka, Takashi ^a,b   Bryant, Jerry L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Chelation; Glucosamine; Hexosamine pathway; PET; SPECT; Theranostic

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GLUCOSAMINE DERIVATIVE; HEXOSAMINE; MOLYBDENUM 99; RADIOISOTOPE; RHENIUM 188; TECHNETIUM 99M; TRACER;

BIOSYNTHESIS; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; CHELATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOPLASM; DRUG STRUCTURE; ECHOGRAPHY; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CHELATING AGENTS; GLUCOSAMINE; HEXOSAMINES; HUMANS; MOLECULAR IMAGING; NEOPLASMS; NUCLEAR MEDICINE;

EID: 84863756002     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801215900     Document Type: Review

References (63)

1. Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev, 2008;27(4):545-54.
2. Delbeke D., et al., Procedure guideline for tumor imaging with 18F-FDG PET/CT. J Nucl Med, 2006;47(5):885-95.
3. Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med. 1991;32:623-48.
4. 99mTc-EC-endostatin. Cancer Biother Radiopharm 2002;17:233-245.
5. 99mTc-labeled C225 in Patients with Squamous Cell Carcinoma of the Head and Neck. J Nucl Med 2004;45(10):1683-7
6. Gong J, Yang DJ, Kohanim S, Humphreys R, et al. Novel in vivo imaging demonstrates upregulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Molecular Cancer Therapeutics 2006;5(12):2991-3000.
7. 99mTc-labeled metronidazole. Pharm Res 1999;16(5):743-750.
8. 99mTc- metronidazole. Stroke, 2003;34:982-986.
9. Ito M, Yang DJ, Mawlawi O, et al. PET and planar imaging of tumor hypoxia with labeled metronidazole. Academic Radiology 2006;13(5):598-609.
10. 99mTC EC Annexin V: Preliminary Clinical Study Targeting Apoptosis in Breast Tumors. Applied Radiation and Isotopes 2008; 66:1175-1182.
11. 99mTc annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg. 1998; 116:844-853. 99m
12. Yang DJ, Ozaki K, Oh C-S, et al. Tc-EC-Guanine: Synthesis, Biodistribution and Tumor Imaging in Animals. Pharmaceutical Research 2005;22 (9):1471-1479.
13. 99mTc-GAP-EDL. Eur J Nucl Med Mol Imaging 2007;34:354-362.
14. Wu JY, Yang DJ, Angelo LS, et al. Molecular imaging of Bcr-Abl phosphokinase in a xenograft model. Molecular Cancer Therapeutics 2009;8(3):703-10.
15. Knoess C, Siegel S, Smith A, et al. Performance evaluation of the microPET R4 PET scanner for rodents. Eur. J. Nucl. Med. Mol. Imaging, 2003; 30, 737-747.
16. 68Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 2001; 28, 1751-7.
17. Bernhardt P, Benjegard SA, Koelby L, et al. Dosimetric comparison of radionuclides for therapy of somatostain receptor-expressing tumors. Nucl. Med. Commun 2000;21:566.
18. Buchman I, Bunjes D, Seitz U, et al, Radioimmunotherapy for myeloablation prior to stem cell transplantation with Re-188 CD 66 a, b, c, d, e antibody in high risk leukemia patients. Eur. J. Nucl. Med. 2000;27:S81.
19. Wang SJ, Lin WY, Chen MN, et al. Rhenium-188 microsphere: a new radiation synovectomy agent. Nucl. Med. Communication 1998;19:427-433.
20. Wang SJ, Lin WY, Hsieh BT, et al. Rhenium-188 sulfur colloid as a radiation synovectomy agent. European J. Nucl. Med. 1995;22:505-507.
21. 188Re for hepatic tumor therapy. Appl. Radiat. Isot. 1996;47:267-271.
22. Wang SJ, Lin WY, Chen MN, et al. Intratumoral injection of rhenium-188 microspheres into an animal model of hepatoma. J. Nucl. Med. 1998;39:1572-1577.
23. Maxon HR, Schroder LE, Washburn LC, et al, Rhenium-188(Sn)HEDP for treatment of osseous metastases. J. Nucl. Med. 1998;39:659-663.
24. Palmedo H, Guhlke S, Bender H, et al, Dose escalation study with rhenium-188 hydroxyethlidene diphosphonate in prostate cancer patients with osseous metastases. European J. Nucl. Med. 2000;27:123-130.
25. Canet EP, Casali C, Desenfant A, et al. Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI. Magn Reson Med. 2000;43(3):403-409.
26. Mang'era K, VanbilloenH, Cleynhens B, et al. Synthesis and Evaluation of the 99mTc-Complexes of L-Cysteine Acetyldiglycine (a Hybrid of MAG3 and L, L-EC) and of L-ß-Homocysteine Acetyldiglycine. Nuclear Medicine & Biology 2000;27: 781-789.
27. 99mTc- Methoxyisobutylisonitrile chest imaging of small cell lung carcinoma: relation to patient prognosis and chemotherapy response-a preliminary report. Cancer. 1998;83:64-68.
28. 99mTc-DMSA renal cortex scan to detect renal damage in women with type 2 diabetes. J Diabetes Complications. 2003;17:297-300.
29. 99mTc-HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med. 1999; 26(10):1251-1258.
30. 99mTc-L, L-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med. 1993;20:738-46.
31. 99mTc-L, L-ethylenedicysteine. Nuclear Medicine Biology, 2000;27:207-214.
32. 99mTc-Ethylenedicysteine- Folate: A new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biotherapy and Radiopharm. 1998;13: 427-435.
33. 99mTc-labeled celebrex. Anti-Cancer Drugs 2004;15:255-263.
34. 99mTc-EC-AMT as an imaging probe for amino acid transporter systems in breast cancer. Nuclear Medicine Communications. 2010;31(8):699-707.
35. Anderson CJ, John CS, Li YJ, et al. N, N-Ethylene-di-L-cysteine (EC) complexes of Ga(III) and In(III): molecular modeling, thermodynamic stability and in vivo studies. Nucl Med Biol 1995: 22:165-173.
36. Sun Y, Anderson CJ, Pajeau TS, et al. Indium (III) and gallium (III) complexes of bis(aminoethanethiol) ligands with different denticities: stabilities, molecular modeling, and in vivo behavior. J Med Chem 1996: 39:458-470.
37. Gong J, Yang DJ, Kohanim S, Angelo LS, Kurzrock R Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model. Cancer Biology Therapy. 2009;8(23):1-9.
38. 99mTc-EC-Annexin V Cancer Biotherapy Radiopharm 2001;16(1):73-84.
39. 99mTc-ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs 2003;14:49-56.
40. 18F-2-Deoxy-d-Glucose positron emission tomography-computed tomography in lung cancer. Semin Roentgenol. 2011; 6(3):208-23.
41. Khan N, Islam MM, Mahmood S, et al. 18F-fluorodeoxyglucose uptake in tumor. Mymensingh Med J. 2011; 20(2):332-42.
42. Fang J, Luo XM, Yao HT, et al. Expression of glucose transporter-1, hypoxia-inducible factor-1a, phosphatidylinositol 3-kinase and protein kinase B (Akt) in relation to [(18)F]fluorodeoxyglucose uptake in nasopharyngeal diffuse large B-cell lymphoma: a case report and literature review. J Int Med Res. 2010; 38(6): 2160-8.
43. Chang JM, Lee HJ, Goo JM, et al., False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol, 2006;7(1): 57-69.
44. Rosenbaum SJ, Lind T, Antoch G, False-positive FDG PET uptake-the role of PET/CT. Eur Radiol, 2006;16(5): 1054-65.
45. Marshall S, Bacote V, Traxinger RR Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. J Biol Chem 1991;266:4706-4712.
46. Wells L, Gao Y, Mahoney JA, et al. Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. J Biol Chem 2002;277:1755-1761.
47. Scheepers A, Joost HG, Schürmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr. 2004;28(5):364-71.
48. Wells, L, Vosseller, K, and Hart, GW. Glycosylation of Nucleocytoplasmic Proteins: Signal Transduction and O-GlcNAc. Science. 2001;291, pp. 2376-2378.
49. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 2011;80:825-58.
50. Paterson AJ, Kudlow JE. Regulation of glutamine:fructose-6-phosphate amidotransferase gene transcription by epidermal growth factor and glucose. Endocrinology. 1995;136(7):2809-16.
51. Pal S, Claffey KP, Cohen HT, Mukhopadhyay D. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem 1998;273:26277-26280.
52. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143-160.
53. 99mTc-Labeled S-benzoylmercapto acetyl triglycine N-acetylglucosamine. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US) 2010; 2004-2010.
54. 188Re-DTPA- deoxyglucose as a potential cancer radiopharmaceutical. AJR Am J Roentgenol. 2010;194(3):761-5.
55. 99mTc-DTPA-DG. Cancer Biother Radiopharm. 2008;23(3):363-70.
56. Zhang W, Chen Y, Guo da J, et al. The synthesis of a D-glucosamine contrast agent, Gd-DTPA-DG, and its application in cancer molecular imaging with MRI. Eur J Radiol. 2011;79(3):369-74.
57. 99mTc]-DTPA-DG) as a potential imaging modality for tumors. Appl Radiat Isot. 2006;64(3):342-7.
58. 188Re-DTPA-DG in MCF-7 breast carcinoma and A549 pulmonary carcinoma cells. Cancer Biother Radiopharm. 2007;22(4):543-50.
59. 99mTc-EC-DG Targeted at the Multifunctional Glucose Transport System: Feasibility study with rodents. Radiology 2003;226: 465-473.
60. 99mTc-Ethylenedicysteine-Glucosamine. Cancer Biotherapy Radiopharm. 2004;19(4):444-458.
61. 99mTc-ethylenedicysteine-deoxyglucose in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2009;36 (10):1583-1591.
62. 99mTc-labeled-1-thio-ß-D-Glucose as Melanoma Targeting Agent. Curr Radiopharm. 2011;4(4):355-60.
63. Balkwill FR. The chemokine system and cancer. J Pathol. 2012; 226(2): 148-57.